Phase 1 Open-label Study Evaluating the Safety of CART-EGFR-IL13Rα2 Cells in Patients With Newly Diagnosed, EGFR-Amplified, MGMT-unmethylated Glioblastoma Following Completion of Initial Radiotherapy
Latest Information Update: 11 Jul 2025
At a glance
- Drugs Anti-EGFR/IL-13R alpha-2-CAR-T-cell-therapy-Tmunity-Therapeutics/University-of-Pennsylvania (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
Most Recent Events
- 03 Jul 2025 Planned initiation date changed from 1 Jun 2025 to 1 Jul 2025.
- 01 Jun 2025 New trial record